HOME >> BIOLOGY >> NEWS
Are we mice or men? Gene mutation linked to improving heart failure in mice proves lethal in humans

The goal of molecular medicine is to utilize the wealth of available experimental tools to develop treatments for human disease. Researchers develop animal models of a disease, investigate the underlying biological mechanisms, and conceive and test novel therapies until a successful treatment is found. The treatment strategy is then developed for human trial.

However, what if the outcome of the treatment was profoundly different in humans when compared with mice? Are we failing to consider the critical differences between mouse and man? Two studies published in the March 14 issue of the Journal of Clinical Investigation led by Evangelia Kranias and researchers at the University of Cincinnati reveal that a mutation in the human gene encoding the protein phospholamban (PLN) is linked to heart failure. In striking contrast to previous reports that indicate that "knock-out" or inhibition of PLN is beneficial in mouse models of heart failure, the researchers reveal that humans with mutated forms of PLN develop lethal heart failure.

Heart failure is a leading cause of human morbidity and mortality worldwide and costs close to $18 billion in health-carerelated costs in America each year. Characterized by suppressed calcium cycling in the heart, it impairs the ability of the heart to supply adequate oxygen- and nutrient-rich blood to the body. Calcium regulates the contraction and relaxation of heart muscle and PLN acts to halt calcium cycling at the end of the contraction so that muscles may relax between beats.

Recent experimental successes in mice have generated much enthusiasm for treating an array of conditions that ultimately result in heart failure by "knocking-out" the PLN gene and thereby enhancing calcium cycling.

However, the effect of inhibiting PLN in cases of cardiac hypertrophy (which can progress to heart failure) was unknown.

In the first study, the researchers studied two mouse models of c
'"/>

Contact: Brooke Grindlinger
science_editor@the-jci.org
212-342-9006
Journal of Clinical Investigation
10-Mar-2003


Page: 1 2 3

Related biology news :

1. Genetic mutations linked to the practice of burning coal in homes in China
2. Spontaneous mutation produces new MAO A/B knockout mouse
3. How an insidious mutation fools DNA replication
4. Using statistics to decipher secrets of natural mutation
5. Rare mutations can significantly increase risk factor for heart disease
6. Genetic mutation linked to more aggressive breast cancer found more often in African-Americans
7. LBP-1a gene mutation linked to disruption of normal fetal development
8. Genetic mutation found that is major contributor to type 1 diabetes
9. The mother lode of mutations
10. Gene mutation causes progressive changes to cell structure in children with Progeria
11. Single gene mutation muddying Parkinsons risk forecasts

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/5/2016)...  The Office of Justice Programs, National Institute ... Enhance or Replace Medico Legal Autopsies?" on NIJ.gov.  ... replacing forensic autopsies with postmortem X-ray computed tomography, ... response to recommendations made by The National Academy ... as a potential component of medicolegal death investigations. ...
(Date:11/29/2016)... Nov. 29, 2016 BioDirection, a privately held ... for the objective detection of concussion and other traumatic ... successfully completed a meeting with the U.S. Food and ... test Pre-Submission Package. During the meeting company representatives reviewed ... a precursor to commencement of a planned pilot trial. ...
(Date:11/22/2016)... According to the new market research report "Biometric ... Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), Application, ... is expected to grow from USD 10.74 Billion in 2015 to reach ... and 2022. Continue Reading ... ...
Breaking Biology News(10 mins):
(Date:12/8/2016)...  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ... immunotherapies, today announced financial results for the fiscal ... delivering on our commitment to address an unmet ... are pleased with the early clinical response data ... are focused on advancing our lead program – ...
(Date:12/8/2016)... SAN DIEGO , Dec. 8, 2016 /PRNewswire-USNewswire/ ... treatments for congestive heart failure and type 2 ... license for a novel adeno-associated virus (AAV) vector ... Kay , M.D., Ph.D., at Stanford University. The ... of its paracrine gene therapy product pipeline. ...
(Date:12/8/2016)... OXFORD, England , December 8, 2016 /PRNewswire/ ... (OGT), das Unternehmen für Molekulargenetik, erweitert seine Palette ... SureSeq myPanel™ NGS Custom FH Panels, das ein ... Hypercholesterinämie (FH) ermöglicht. Das Panel bietet eine Erkennung ... Number Variations (CNV) mit einem einzigen kleinen Panel ...
(Date:12/8/2016)... Maryland (PRWEB) , ... December ... ... announces the commercial launch of flexible packaging for their exceptionally efficient ... disposable bag system extends RoosterBio’s portfolio of bioprocess media products engineered to ...
Breaking Biology Technology:
Cached News: